KL-6 has been used and validated as a potential biomarker for diagnosing and indicating the severity and progression of ILD, particularly in idiopathic interstitial pneumonia, including idiopathic pulmonary fibrosis (IPF)23–26. This evidence concerns the gene MUC1 and idiopathic interstitial pneumonia.